Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis

J. D. Nelson, H. Kusmiesz, S. Shelton

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


A review of the literature concerning shigellosis treated with trimethoprim-sulfamethoxazole (TMP-SMZ) revealed comparative studies of 149 cases and noncomparative studies of 147 cases. Bacteriologic and clinical success rates were ⩾90% and TMP-SMZ compared favorably with alternative drug therapy. In the present study TMP-SMZ was given intravenously as initial therapy to 11 children hospitalized for severe shigella colitis. Bacteriologic and clinical responses were comparable to those observed with oral TMP-SMZ therapy. Pharmacokinetic studies revealed substantial differences between the responses of these children and those reported for adult patients; a higher ratio of SMZ to TMP (50:1) was found in children. It is concluded that TMP-SMZ is effective therapy for shigellosis and is the drug of choice in areas where ampicillin resistance is prevalent.

Original languageEnglish (US)
Pages (from-to)546-550
Number of pages5
JournalReviews of infectious diseases
Issue number2
StatePublished - Mar 1982

ASJC Scopus subject areas

  • Microbiology (medical)


Dive into the research topics of 'Oral or intravenous trimethoprim-sulfamethoxazole therapy for shigellosis'. Together they form a unique fingerprint.

Cite this